Jover Placid sold $447K of TEVA

Jover Placid (See "Remarks") sold 12,827 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.88 ($0.45M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jover Placid
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEVA
Neutral
high confidence
Mentioned
$TEVA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and total value, plus confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the disclosed insider sale, but the 10b5-1 structure generally limits actionable fundamental impact.

03

What to watch

The article provides no context on overall insider holdings, whether sales are part of scheduled diversification, or whether other insiders are buying.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for TEVA, reported by officer Jover Placid.

Company-level read

Ticker impact

$TEVANeutralHigh confidence
Context

Form 4 shows insider Jover Placid sold 12,827 TEVA shares on 2026-08-03 at $34.8757, totaling about $447.4K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction and explicitly notes a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still be monitored as a weak sentiment signal if it clusters with other negative disclosures.

Key entities

  • TEVA PHARMACEUTICAL INDUSTRIES LTD

    Subject of the Form 4 insider transaction disclosure.

  • Jover Placid

    Officer who sold 12,827 shares of TEVA under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEVAMed

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights

Teva Pharmaceutical (TEVA) reported a 2% revenue decline in Q3 2026, driven by a 16% drop in generics revenue. The company discontinued a Phase II study and faces challenges with AUSTEDO revenue due to pricing pressures. CEO Richard Francis and CFO Eli Kalif discussed gross margin expansion, IRA impact, and growth drivers like UZEDY, AJOVY, and WELTRUZA. Teva expects AUSTEDO to reach $2.5B in 2027 and over $3B at peak, despite litigation risks and biosimilar challenges.

$TEVAHighAI 8/10

H.C. Wainwright raises Teva Pharma stock price target to $54

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

$TEVAMed

Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.